Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over timeMar. 17, 2017
ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.
The SPIRE 1 and SPIRE 2 trials were presented during Late-Breaking Clinical Trial Session 1 (March 17), ACC 2017, Washington DC, USA
Recorded at ACC 2017, Washington DC, USA.
Dr. Paul M. Ridker (Co-chair Executive Committee, SPIRE clinical trials program and director for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, MA, USA)